ZymoGenetics, Inc. (Nasdaq: ZGEN) today announced that it has priced an underwritten public offering of 14,000,000 shares of its common stock at a price of $6.00 per share. Net proceeds, after estimated underwriting discounts and commissions and estimated expenses, will be approximately $79,000,000.
ZymoGenetics has granted the underwriters a 30-day option to purchase up to an additional 2,100,000 shares of common stock to cover overallotments, if any. The offering is expected to close on or about January 12, 2010, subject to satisfaction of customary closing conditions. Leerink Swann LLC is acting as sole book-running manager for the offering. Wedbush Morgan Securities, Inc., William Blair & Company, L.L.C., Canaccord Adams Inc. and McAdams Wright Ragen, Inc. are acting as co-managers for the offering.
The securities described above are being offered by ZymoGenetics pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The offering may be made only by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained, when available, from Leerink Swann LLC , Attention: Syndicate Department, One Federal Street, 37th Fl., Boston, MA 02110 or by calling Leerink Swann LLC, toll free, at 1-800-808-7525, Ext. 4814.